Xeltis has raised a further €20.5 million to expand manufacturing and European deployment of its aXess vascular access conduit while advancing a US pivotal trial and preparing for regulatory submission.
Led by Horizon 3 Healthcare, the financing also includes support from the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita, and existing shareholders. It follows approximately €50 million secured during 2025 from the European Investment Bank and other investors.
Xeltis develops synthetic vascular implants using its Restorex polymer platform. The porous scaffold provides an initial mechanical structure while the patient’s cells grow through it, after which the polymer is gradually absorbed and newly formed tissue is intended to assume the function of the device.
Designed to create vascular access for haemodialysis, the aXess conduit has received CE marking and entered commercial deployment in Europe. The first commercial patient was treated in Germany during July, moving Xeltis from clinical development into routine supply and support.
Part of the additional capital will increase manufacturing capability as European use expands. Funding will also complete the ongoing US pivotal trial, support preparation for an FDA submission and potential launch, and advance the company’s XABG and XPAD vascular programmes.
Clinical approval transfers pressure to production
Medical technology companies can spend years demonstrating that an implant performs safely before manufacturing consistency becomes the dominant constraint. A bioresorbable vascular scaffold is particularly sensitive because material chemistry, pore structure, dimensions, mechanical properties, sterilisation, and packaging may all influence behaviour after implantation.
Commercial scale-up must reproduce the characteristics evaluated during clinical studies. Higher throughput, new equipment, additional suppliers, or changes in production location can introduce variation that was absent from early batches, requiring validation that the finished conduit remains within clinically relevant limits.
Raw polymer controls extend beyond standard incoming inspection. Molecular properties, processing history, storage, contamination, and environmental exposure can affect how the material behaves during manufacture and how predictably it is absorbed after implantation.
Manufacturing must also hold the conduit’s dimensions and porous structure consistently, since both influence mechanical performance and tissue infiltration. Inspection may combine dimensional measurement, imaging, material testing, and process monitoring, while destructive tests require representative sampling rather than examination of every finished device.
Sterilisation introduces another controlled variable. The method must achieve the required sterility assurance without changing polymer strength, degradation, surface condition, or geometry, while packaging must preserve those properties throughout transport and storage.
Traceability extends from raw materials and machine conditions through inspection, sterilisation, packaging, distribution, and implantation. Individual devices may need to remain identifiable for years, particularly where clinical follow-up assesses tissue formation, patency, infection, degradation, and the need for further intervention.
European deployment also depends on procurement, training, inventory, and clinical implementation. CE marking permits commercial use, but hospitals and dialysis providers still need evidence on procedure time, patient selection, support, cost, and availability before adopting a new conduit routinely.
Other implant developers face the same transition from regulatory approval into controlled supply. European market access for the PRIMA retinal implant has similarly brought manufacturing, clinical training, distribution, and long term support into the foreground.
The US pivotal study creates parallel demands because clinical sites need consistent products and documentation while data is collected for a future submission. Manufacturing changes made during enrolment may require comparison or additional evidence to show that later devices remain equivalent to those initially studied.
Xeltis’ technology also requires long term observation, because the intended replacement of the polymer scaffold by patient tissue occurs gradually. Early mechanical performance and later biological remodelling must both be assessed, extending the period over which manufacturing and clinical data need to remain connected.
The new capital consequently supports several expensive activities at once: manufacturing equipment, validation, clinical trials, regulatory preparation, quality systems, commercial inventory, training, and additional product development. Expansion into coronary bypass and peripheral arterial applications could widen the platform’s use, but each indication requires its own design controls and evidence.
With European commercial supply under way, Xeltis must increase output without weakening the material and process controls established during development. Results from the US trial and performance of the first commercial implants will determine how rapidly further production capacity needs to come online.
